The rubella diagnostic testing global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Rubella Diagnostic Testing Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The rubella diagnostic testing market size has grown strongly in recent years. It will grow from $1.22 billion in 2023 to $1.30 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to a rise in vaccination programs, a rising incidence of immunization-preventable outbreaks, government initiatives to combat the rubella virus, and the expansion of diagnostic testing in non-traditional settings.
The rubella diagnostic testing market size is expected to see strong growth in the next few years. It will grow to $1.68 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing healthcare expenditure, growing focus on preventive healthcare, rising awareness of vaccine-preventable diseases, growing public health campaigns, and expansion of telemedicine and remote diagnostics. Major trends in the forecast period include advancements in diagnostic technologies, technological integration in healthcare systems, development of point-of-care testing solutions, development of new diagnostic methods, and advancements in molecular diagnostics.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/rubella-diagnostic-testing-global-market-report
Scope Of Rubella Diagnostic Testing Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Rubella Diagnostic Testing Market Overview
Market Drivers –
The rising cases of viral infections are expected to propel the growth of the rubella diagnostic testing market going forward. Viral infections are illnesses caused by viruses, tiny infectious agents that can only replicate inside the living cells of an organism. The rising cases of viral infections are due to increased global travel, which facilitates the spread of viruses across borders, and climate change, which alters vector habitats and extends the range of disease-carrying organisms. Rubella diagnostic testing helps identify and manage rubella infections early, preventing complications, particularly in pregnant women, and aiding in outbreak control to reduce virus spread. For instance, in December 2023, according to the National Health Service, a UK-based government department, the number of daily hospital admissions for flu averaged 234, marking a 53% increase from the previous week, while hospital cases of norovirus rose by 15% to an average of 406 daily, reflecting a 28% increase from the same week last year. Therefore, the rising cases of viral infections are driving the growth of the rubella diagnostic testing market.
Market Trends –
Major companies operating in the rubella diagnostic testing market are focusing on developing innovative solutions, such as a rubella virus vaccine, to enhance diagnostic accuracy and improve preventive measures. The rubella virus vaccine is a vaccine that provides immunity against rubella, often administered as part of the MMR or MMRV combination vaccines to prevent the disease and associated complications. For instance, in March 2023, Merck & Co., Inc., a US-based pharmaceutical company, received FDA approval for the intramuscular (IM) administration of Merck’s M-M-R II vaccine, which is crucial in protecting against rubella, along with measles and mumps. This approval allows healthcare providers to administer the rubella vaccine using the IM route, making it consistent with other routinely recommended pediatric vaccines. Rubella vaccination is essential for preventing outbreaks and protecting against the severe complications the virus can cause, particularly in pregnant women.
The rubella diagnostic testing market covered in this report is segmented –
1) By Diagnostic Technique: Latex Agglutination, Liver Function Tests, Enzyme Immunoassay (EIA), Radioimmunoassay (Ria), Fluorescent Immunoassay (FIA), Other Diagnostic Techniques
2) By Age Group: Neonates, Teenagers, Adults
3) By End User: Hospitals And Clinics, Cancer Diagnostic Centers, Ambulatory Surgical Centers, Other End Users
Get an inside scoop of the rubella diagnostic testing market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=19177&type=smp
Regional Insights –
North America was the largest region in the rubella diagnostic testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rubella diagnostic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the rubella diagnostic testing market are Cardinal Health Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., bioMérieux S.A., Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc., DiaSorin S.p.A., Meridian Bioscience Inc., Fortress Diagnostics Ltd., Mylab Discovery Solutions Pvt. Ltd., MP Biomedicals LLC, CTK Biotech Inc., ZEUS Scientific Inc., Creative Diagnostics, Arlington Scientific Inc., AccuBioTech Co. Ltd., Intec Products Inc., Vitrosens Biotechnology Ltd., Sprint Diagnostics Pvt. Ltd., InDevR Inc., Atlas Medical GmbH
Table of Contents
1. Executive Summary
2. Rubella Diagnostic Testing Market Report Structure
3. Rubella Diagnostic Testing Market Trends And Strategies
4. Rubella Diagnostic Testing Market – Macro Economic Scenario
5. Global Rubella Diagnostic Testing Market Size and Growth
.
.
.
32. Global Rubella Diagnostic Testing Market Competitive Benchmarking
33. Global Rubella Diagnostic Testing Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Rubella Diagnostic Testing Market
35. Rubella Diagnostic Testing Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
